For cancers like NSCLC, where immunotherapy and chemoimmunotherapy serve as alternative standard options, patients with favorable prognosis based on low TF and advantageous immunotherapy biomarkers could opt for immunotherapy alone to avoid chemotherapy toxicity. The gene discussed is TF; the disease is cancer.